TEVA ANNOUNCES TENTATIVE APPROVAL OF RISEDRONATE TABLETS

Teva Pharmaceutical has announced that the FDA has granted tentative approval for its Risedronate Sodium Tablets, 5 mg, 30 mg and 35 mg. Final approval is expected upon the resolution of pending patent litigation.

Teva's Risedronate Sodium Tablets are the AB-rated generic equivalent of Procter & Gamble's Actonel tablets, a product indicated for treatment and prevention of postmenopausal and glucocorticoid-induced osteoporosis, and treatment of Paget's disease.